of more intensive lowering of LDL cholesterol. The Lancet, 376(9753), 1670-1681. 12. Seidah, N. G., & Prat, A. (2012). The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery, 11(5), 367-383. 13. Sabatine, M. S., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713-1722. 14. Cannon, C. P., et al. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine, 372(25), 2387-2397. 15. Rubins, H. B., et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. New England Journal of Medicine, 341(6), 410-418. 16. Estruch, R., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extravirgin olive oil or nuts. New England Journal of Medicine, 378(25), e34. 17. Kodama, S., et al. (2007). Effect of aerobic exercise training on serum levels of highdensity lipoprotein cholesterol. Archives of Internal Medicine, 167(10), 999-1008. 18. Hujová, J. (2013). The impact of smoking on lipid profile in adolescents. Physiological Research, 62(2), 193-198. 19. Dattilo, A. M., & Kris-Etherton, P. M. (1992). Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. The American Journal of Clinical Nutrition, 56(2), 320328. 20. Steptoe, A., & Kivimäki, M. (2012). Stress and cardiovascular disease. Nature Reviews Cardiology, 9(6), 360-370. 21. Conroy, R. M., et al. (2003). Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal, 24(11), 987-1003. 22. Smith, S. C., et al. (2011). AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease. Journal of the American College of Cardiology, 58(23), 24322446. 23. Barter, P. J., et al. (2007). Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine, 357(21), 2109-2122. 24. Ray, K. K., et al. (2017). Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. New England Journal of Medicine, 376(15), 1430-1440. Kapitola: Současná věda a cholesterol dnes 800 182 572 7:30-16:30 (Pá: do14:00) Vyhlídka 39, 63800 Brno, Česká republika Tel: +420 545 222 863 Fax: +420 545 222 011 www.vitaminy-mineraly.cz Strana 32
RkJQdWJsaXNoZXIy Nzg5MDg=